---
title: "Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Specific populations questions"
description: "Specific populations questions on Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pediatric use. Questions: What is the Imbruvica dose for liver impairment in CLL? Is Imbruvica approved for children with CLL? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Specific populations questions

Manufacturer: Pharmacyclics LLC; Janssen Biotech, Inc.  
Prescribing information: [Imbruvica](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf)

Specific populations questions that apply to every indication of Imbruvica are on [Imbruvica (ibrutinib), all indications: Specific populations](https://www.evicenter.com/medical-information/imbruvica/specific-populations).

## Specific populations

<a id="imbruvica-hepatic-dose"></a>

### What is the Imbruvica dose for liver impairment in CLL?

> “The recommended dose is:
> 140 mg daily for patients with mild hepatic impairment (Child-Pugh class A)
> 70 mg daily for patients with moderate hepatic impairment (Child-Pugh class B)
> For patients with mild or moderate hepatic impairment, monitor more frequently for adverse reactions of IMBRUVICA<sup>®</sup>
>
> Avoid the use of IMBRUVICA<sup>®</sup> in patients with severe hepatic impairment (Child-Pugh class C).”

Source: [IMBRUVICA: Additional Dosing Info - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/additional-dosing-information#:~:text=The%20recommended%20dose%20is%3A,hepatic%20impairment%20%28Child%2DPugh%20class%20C%29.)

On the page, select: Hepatic impairment

> “The AUC of ibrutinib increased 2.7-fold in subjects with mild hepatic impairment (Child-Pugh 
> class A), 8.2-fold in subjects with moderate hepatic impairment (Child-Pugh class B) and 
> 9.8-fold in subjects with severe hepatic impairment (Child-Pugh class C) relative to subjects with 
> normal liver function. The Cmax of ibrutinib increased 5.2-fold in mild hepatic impairment, 
> 8.8-fold in moderate hepatic impairment and 7-fold in severe hepatic impairment relative to 
> subjects with normal liver function [see Use in Specific Populations (8.6)].”

Source: [IMBRUVICA: Prescribing information, page 36, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=36)

## Pediatric use

<a id="imbruvica-children-cll"></a>

### Is Imbruvica approved for children with CLL?

> “The safety and effectiveness of IMBRUVICA in pediatric patients have not been established in 
> CLL/SLL, CLL/SLL with 17p deletion, or WM.”

Source: [IMBRUVICA: Prescribing information, page 32, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=32)

## Related pages
- [Medical information: Imbruvica (ibrutinib): Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma)
- [Indication](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/guidelines)
